Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis.

[1]  P. Wallén,et al.  In vivo metabolism of human tissue-type plasminogen activator. , 2009, Scandinavian journal of haematology.

[2]  C. Alessandri,et al.  Improvement of some blood coagulation factors in cirrhotic patients treated with low doses of heparin. , 2009, Scandinavian journal of haematology.

[3]  R. Scorza,et al.  Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders , 1993, British journal of haematology.

[4]  S. Basili,et al.  Hyperfibrinolysis Resulting from Clotting Activation in Patients with Different Degrees of Cirrhosis , 1993, Hepatology.

[5]  A. Tripodi,et al.  Multicentric Evaluation of a New Assay for Prothrombin Fragment F1+2 Determination , 1992, Thrombosis and Haemostasis.

[6]  J. Wilson,et al.  Disseminated intravascular coagulation in liver cirrhosis. , 1992, Journal of hepatology.

[7]  S. Basili,et al.  Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis , 1992, Hepatology.

[8]  F. Leebeek,et al.  A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. , 1991, Gastroenterology.

[9]  J. Lasierra,et al.  Tissue Plasminogen Activator and Plasminogen Activator Inhibitor in Patients with Liver Cirrhosis , 1991 .

[10]  C. Bode,et al.  Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. , 1991, Journal of hepatology.

[11]  D. Triger.  Endotoxemia in liver disease--time for re-appraisal? , 1991, Journal of hepatology.

[12]  W. Stüber,et al.  Determination of Human Prothrombin Activation Fragment 1+2 in Plasma with an Antibody against a Synthetic Peptide , 1991, Thrombosis and Haemostasis.

[13]  H. Büller,et al.  Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways , 1990 .

[14]  T. van der Poll,et al.  Activation of coagulation after administration of tumor necrosis factor to normal subjects. , 1990, The New England journal of medicine.

[15]  F. Ofosu,et al.  A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin–antithrombin complex, D‐dimer and fibrinogen/fibrin fragment E antigen , 1990, British journal of haematology.

[16]  J. M. Carr.  Disseminated intravascular coagulation in cirrhosis , 1989, Hepatology.

[17]  A. Cerami,et al.  Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.

[18]  M. Kutner,et al.  Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis , 1988, Hepatology.

[19]  A. Haeberli,et al.  Relationship Between Fibrinopeptide A and Fibrinogen/Fibrin Fragment E in Thromboembolism, DIC and Various Non-Thromboembolic Diseases , 1987, Thrombosis and Haemostasis.

[20]  K. Bauer,et al.  The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. , 1987, Blood.

[21]  R. Francis,et al.  The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor. , 1987, Blood.

[22]  C. Alessandri,et al.  Prekallikrein and factor VII as prognostic indexes of liver failure. , 1986, American journal of clinical pathology.

[23]  J. T. ten Cate,et al.  alpha 2-Plasmin inhibitor metabolism in patients with liver cirrhosis. , 1985, The Journal of laboratory and clinical medicine.

[24]  A. Mantovani,et al.  Direct induction of tissue factor synthesis by endotoxin in human macrophages from diverse anatomical sites. , 1983, Immunology.

[25]  N. Semeraro,et al.  Cultured human endothelial cells generate tissue factor in response to endotoxin. , 1983, The Journal of clinical investigation.

[26]  P. Mannucci,et al.  Significance of plasma fibrinopeptide A and high molecular weight fibrinogen in patients with liver cirrhosis , 1982, British journal of haematology.

[27]  K. Bauer,et al.  Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. , 1982, Blood.

[28]  J. T. ten Cate,et al.  Quantitative Endotoxin Determination In Blood With A Chromogenic Substrate , 1981, Thrombosis and Haemostasis.

[29]  P. Straub,et al.  Exchange between intravascularly and extravascularly injected radioiodinated fibrinogen and its in vivo derivatives. , 1980, The Journal of laboratory and clinical medicine.

[30]  L. Poller,et al.  Association of abnormal fibrin polymerisation with severe liver disease. , 1977, Gut.

[31]  J. Nolan,et al.  The role of endotoxin in liver injury. , 1975, Gastroenterology.

[32]  M. Pasmantier,et al.  Fibrinogen survival in cirrhosis: improvement by "low dose" heparin. , 1975, Annals of internal medicine.

[33]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[34]  J. Fine,et al.  ON THE ABSORPTION OF BACTERIAL ENDOTOXIN FROM THE GASTRO-INTESTINAL TRACT OF THE NORMAL AND SHOCKED ANIMAL , 1960, The Journal of experimental medicine.

[35]  S. Basili,et al.  Prevalence of hyperfibrinolysis in patients with liver cirrhosis , 1993 .

[36]  C. Cordova,et al.  Clotting abnormalities in chronic liver disease. , 1992, Digestive diseases.

[37]  C. Bode,et al.  Chromogenic Endotoxin Assay in Plasma. Selection of Plasma Pretreatment and Production of Standard Curves , 1989, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[38]  M. Alessi,et al.  Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. , 1988, Blood.

[39]  R. Colman,et al.  Hemostasis and Thrombosis: Basic Principles and Clinical Practice , 1988 .

[40]  C. Esmon,et al.  Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. , 1987, The Journal of clinical investigation.

[41]  C. Bode,et al.  Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. , 1987, Journal of hepatology.

[42]  E. Brommer,et al.  Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage , 1986, Hepatology.

[43]  D. Martines,et al.  Bleeding in cirrhotic patients: a precipitating factor due to intravascular coagulation or to hepatic failure? , 1983, Haemostasis.

[44]  H. Liehr.  Endotoxins and the pathogenesis of hepatic and gastrointestinal diseases. , 1982, Ergebnisse der inneren Medizin und Kinderheilkunde.